Kiromic BioPharma, Inc. ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical ...

Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. The ...

This article explores some of the challenges in developing cell lines for therapeutics, such as cell line stability, and how ...

The secondary endpoint of mPFS was 7.7 months across all patients (5.6 months at 40mg and 6.6 months at 60mg; mPFS remains unreached at 80mg). The exploratory biomarker of CXCL13, a B-cell chemokine ...